Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients With Cancer-Associated Thromboembolism Treated With Rivaroxaban

Bayer1,000 enrolled

Overview

To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

Venous Thromboembolism

Interventions

Rivaroxaban (Xarelto, BAY59-7939)DRUG

15/20 mg

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients (≥18 years-of-age) with active cancer * Patient with at least one index venous thromboembolism (VTE ) * ≥6-months of continuous eligibility prior to the index VTE event (baseline period). * Newly initiated on rivaroxaban Exclusion Criteria: * Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date * Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period

Locations (1)

US database

New York, New York, United States

Outcomes

Primary Outcomes

Recurrent Venous thromboembolism

Derived using inpatient and outpatient medical claims

Time frame: Retrospective analysis from November 2012 through September 2015

Bleeding (based on the Cunningham algorithm)

Derived using inpatient and outpatient medical claims

Time frame: Retrospective analysis from November 2012 through September 2015

Mortality (In-hospital mortality or need for hospice care without subsequent healthcare claims)

Derived using inpatient and outpatient medical claims

Time frame: Retrospective analysis from November 2012 through September 2015

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.